Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.6K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.6K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.1K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.1K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.8K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.8K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.8K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective Audit and Feedback of Targeted Antimicrobials Use at a Tertiary Care Hospital in the United Arab Emirates.

Antibiotics (Basel, Switzerland)·2025
Same author

Sulopenem Etzadroxil/Probenecid.

Hospital pharmacy·2025
Same author

Axatilimab.

Hospital pharmacy·2025
Same author

Respiratory Syncytial Virus Vaccine (mRNA).

Hospital pharmacy·2024
Same author

Resmetirom.

Hospital pharmacy·2024
Same author

Cefepime/Enmetazobactam.

Hospital pharmacy·2024
Same journal

Stability of Diluted Intravenous Metronidazole in 0.9% Sodium Chloride.

Hospital pharmacy·2026
Same journal

Response to Comment on "Early Versus Later Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials".

Hospital pharmacy·2026
Same journal

Significant Published Articles in 2025 for Pharmacy Nutrition Support Practice.

Hospital pharmacy·2026
Same journal

Comment on "Early Versus Later Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials".

Hospital pharmacy·2026
Same journal

Comparison of Cystatin C-Based and Serum Creatinine-Based Renal Function Estimates Against Timed Urine Collection in Critically Ill Patients.

Hospital pharmacy·2026
Same journal

Comment on "Pharmacy Physiotherapy Interprofessional Education and Practice".

Hospital pharmacy·2026
See all related articles

Related Experiment Video

Updated: Mar 25, 2026

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

2.6K

Ivadradine.

Dennis J Cada1, Ross Bindler2, Danial E Baker3

  • 1Founder and Contributing Editor, The Formulary.

Hospital Pharmacy
|February 26, 2016
PubMed
Summary
This summary is machine-generated.

The Formulary Monograph Service provides monthly drug monographs and utilization evaluations for Pharmacy & Therapeutics Committees. This service aids in informed drug selection and safe medication use evaluations for healthcare facilities.

More Related Videos

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

9.4K
Digital Droplet PCR Method for the Quantification of AAV Transduction Efficiency in Murine Retina
09:50

Digital Droplet PCR Method for the Quantification of AAV Transduction Efficiency in Murine Retina

Published on: December 25, 2021

5.3K

Related Experiment Videos

Last Updated: Mar 25, 2026

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

2.6K
Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

9.4K
Digital Droplet PCR Method for the Quantification of AAV Transduction Efficiency in Murine Retina
09:50

Digital Droplet PCR Method for the Quantification of AAV Transduction Efficiency in Murine Retina

Published on: December 25, 2021

5.3K

Area of Science:

  • Pharmaceutical Science
  • Clinical Pharmacy
  • Drug Information

Background:

  • Healthcare facilities require timely and accurate drug information for formulary management.
  • Pharmacy and Therapeutics (P&T) Committees need evidence-based data for drug approval and utilization decisions.
  • The Formulary Monograph Service addresses the need for comprehensive drug evaluation resources.

Purpose of the Study:

  • To provide subscribers with detailed monographs on new and emerging drugs.
  • To offer concise summaries for pharmacy and nursing in-service education.
  • To deliver thorough drug utilization evaluations (DUE/MUE) for optimizing medication use.

Main Methods:

  • Publication of 5-6 in-depth monographs on drugs in late-stage trials or recently released.
  • Inclusion of 1-page summary monographs for quick reference and educational purposes.
  • Generation of a comprehensive drug utilization evaluation/medication use evaluation (DUE/MUE) monthly.

Main Results:

  • Subscribers receive print and online access to monographs and evaluations.
  • Customization options are available to meet specific facility needs.
  • A monthly drug class review is now integrated into the service.

Conclusions:

  • The Formulary Monograph Service is a valuable resource for P&T Committees and healthcare professionals.
  • The service supports evidence-based formulary management and medication safety.
  • Timely drug information and utilization reviews are crucial for effective pharmacy practice.